Fenpropathrin Induces GLT-1 Ubiquitination and Increases IL-6 Secretion through the Mdm2-p53 Pathway.

Human exposure to fenpropathrin, a widely used pesticide, is linked to Parkinson's-like symptoms in the body. However, a specific pathogenic mechanism is still unclear. This study found that fenpropathrin increased the expression of murine double minute 2 (Mdm2) and reduced the expression of p53. Fenpropathrin stimulated the expression of neural precursor cell expressed, developmentally down-regulated 4-like (Nedd4L) and promoted the secretion of the inflammatory cytokine interleukin-6 (IL-6) through the Mdm2-p53 pathway. Nedd4L, a ubiquitin ligase, mediated the ubiquitination degradation of glutamate transporter 1 (GLT-1), resulting in glutamate accumulation and excitotoxicity aggravation. Our findings elucidate part of the pathogenic mechanism of fenpropathrin toxicity and provide scientific evidence to help develop guidance for pesticide control and environmental protection.

[1]  Bin Wang,et al.  Farnesoid X receptor functions in cervical cancer via the p14ARF-mouse double minute 2-p53 pathway , 2022, Molecular Biology Reports.

[2]  Shaogang Qu,et al.  Role of autophagy and oxidative stress to astrocytes in fenpropathrin-induced Parkinson-like damage , 2021, Neurochemistry International.

[3]  Fushun Wang,et al.  Molecular Mechanisms of Glutamate Toxicity in Parkinson’s Disease , 2020, Frontiers in Neuroscience.

[4]  L. Lao,et al.  Botanical Drug Puerarin Promotes Neuronal Survival and Neurite Outgrowth against MPTP/MPP+-Induced Toxicity via Progesterone Receptor Signaling , 2020, Oxidative medicine and cellular longevity.

[5]  Zhentao Zhang,et al.  Asparagine endopeptidase inhibitor protects against fenpropathrin-induced neurodegeneration via suppressing α-synuclein aggregation and neuroinflammation. , 2020, European journal of pharmacology.

[6]  Shaogang Qu,et al.  Fenpropathrin induces degeneration of dopaminergic neurons via disruption of the mitochondrial quality control system , 2020, Cell Death Discovery.

[7]  R. Vemuganti,et al.  Deletion of ubiquitin ligase Nedd4l exacerbates ischemic brain damage , 2020, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  Zhi-wei Wang,et al.  NEDD4 E3 ligase: Functions and mechanism in human cancer. , 2020, Seminars in cancer biology.

[9]  Allegra T. Aron,et al.  MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling , 2020, Genes & development.

[10]  Xin Li,et al.  Targeting MDM2 for novel molecular therapy: Beyond oncology , 2020, Medicinal research reviews.

[11]  H. Mohammed,et al.  Camel milk rescues neurotoxic impairments induced by fenpropathrin via regulating oxidative stress, apoptotic, and inflammatory events in the brain of rats. , 2019, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[12]  M. Aschner,et al.  The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics , 2019, Neuropharmacology.

[13]  I. Dikic,et al.  Cellular quality control by the ubiquitin-proteasome system and autophagy , 2019, Science.

[14]  H. Ali,et al.  Fenpropathrin induces testicular damage, apoptosis, and genomic DNA damage in adult rats: Protective role of camel milk. , 2019, Ecotoxicology and environmental safety.

[15]  Na Hui,et al.  ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation , 2019, Cell Death and Disease.

[16]  Wenlong Zhang,et al.  Paired-Cysteine Scanning Reveals Conformationally Sensitive Proximity between the TM4b-4c Loop and TM8 of the Glutamate Transporter EAAT1. , 2019, ACS chemical neuroscience.

[17]  D. Surmeier,et al.  Cholinergic Interneurons Amplify Thalamostriatal Excitation of Striatal Indirect Pathway Neurons in Parkinson’s Disease Models , 2019, Neuron.

[18]  Denis Gris,et al.  Astrocytes Maintain Glutamate Homeostasis in the CNS by Controlling the Balance between Glutamate Uptake and Release , 2019, Cells.

[19]  F. Tan,et al.  Regulatory Mechanism of miR-543-3p on GLT-1 in a Mouse Model of Parkinson's Disease. , 2019, ACS chemical neuroscience.

[20]  K. Kamiński,et al.  Interleukin 6 Knockout Inhibits Aging-Related Accumulation of p53 in the Mouse Myocardium , 2019, The journals of gerontology. Series A, Biological sciences and medical sciences.

[21]  Mei Zhu,et al.  Parkinson’s disease-linked Parkin mutations impair glutamatergic signaling in hippocampal neurons , 2018, BMC Biology.

[22]  H. Cai,et al.  Parkin and PINK1 mitigate STING-induced inflammation , 2018, Nature.

[23]  H. J. Chung,et al.  Loss of fragile X protein FMRP impairs homeostatic synaptic downscaling through tumor suppressor p53 and ubiquitin E3 ligase Nedd4-2 , 2018, Human molecular genetics.

[24]  Dongmei Mai,et al.  Simvastatin Inhibits Activation of NADPH Oxidase/p38 MAPK Pathway and Enhances Expression of Antioxidant Protein in Parkinson Disease Models , 2018, Front. Mol. Neurosci..

[25]  J. Chatton,et al.  Extracellular Potassium and Glutamate Interact To Modulate Mitochondria in Astrocytes. , 2018, ACS chemical neuroscience.

[26]  Jia Liu,et al.  Piperlongumine restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models , 2018, Autophagy.

[27]  Voon Yee-Lin,et al.  Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment , 2018, Mini reviews in medicinal chemistry.

[28]  Georgia Woods,et al.  Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson ’ s Disease Graphical , 2018 .

[29]  P. Kischel,et al.  Orai3 calcium channel and resistance to chemotherapy in breast cancer cells: the p53 connection , 2018, Cell Death & Differentiation.

[30]  Tanya Chotibut,et al.  Ceftriaxone reduces L‐dopa–induced dyskinesia severity in 6‐hydroxydopamine parkinson's disease model , 2017, Movement disorders : official journal of the Movement Disorder Society.

[31]  H. Clusmann,et al.  Effect of Intrastriatal 6-OHDA Lesions on Extrastriatal Brain Structures in the Mouse , 2017, Molecular Neurobiology.

[32]  Hui Tang,et al.  MDM2 mediates fibroblast activation and renal tubulointerstitial fibrosis via a p53-independent pathway. , 2017, American journal of physiology. Renal physiology.

[33]  A. Hudmon,et al.  Constitutive regulation of the glutamate/aspartate transporter EAAT1 by Calcium‐Calmodulin‐Dependent Protein Kinase II , 2017, Journal of neurochemistry.

[34]  R. Mitra,et al.  Mdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells. , 2017, Cancer research.

[35]  J. Volkmann,et al.  Parkinson disease , 2017, Nature Reviews Disease Primers.

[36]  Juan Shi,et al.  p53 predominantly regulates IL-6 production and suppresses synovial inflammation in fibroblast-like synoviocytes and adjuvant-induced arthritis , 2016, Arthritis Research & Therapy.

[37]  A. Ascherio,et al.  The epidemiology of Parkinson's disease: risk factors and prevention , 2016, The Lancet Neurology.

[38]  David Komander,et al.  Ubiquitin modifications , 2016, Cell Research.

[39]  K. Jewett,et al.  Feedback modulation of neural network synchrony and seizure susceptibility by Mdm2-p53-Nedd4-2 signaling , 2016, Molecular Brain.

[40]  F. Tan,et al.  Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson's Disease , 2016, Neural plasticity.

[41]  K. Jewett,et al.  The tumor suppressor p53 guides GluA1 homeostasis through Nedd4‐2 during chronic elevation of neuronal activity , 2015, Journal of neurochemistry.

[42]  Kou Takahashi,et al.  Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease , 2015, Cellular and Molecular Life Sciences.

[43]  Chunnuan Chen,et al.  Fenpropathrin, a Widely Used Pesticide, Causes Dopaminergic Degeneration , 2016, Molecular Neurobiology.

[44]  R. Barker,et al.  Time course of dopamine neuron loss and glial response in the 6‐OHDA striatal mouse model of Parkinson's disease , 2014, The European journal of neuroscience.

[45]  G. Liguori,et al.  Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer , 2014, Oncogene.

[46]  H. Walden,et al.  Structure of the Human FANCL RING-Ube2T Complex Reveals Determinants of Cognate E3-E2 Selection , 2014, Structure.

[47]  M. Chesselet,et al.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease , 2013, Progress in Neurobiology.

[48]  Tanya Chotibut,et al.  Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model , 2013, Molecular Neurobiology.

[49]  Jiandong Jiang,et al.  Characterization of a fenpropathrin-degrading strain and construction of a genetically engineered microorganism for simultaneous degradation of methyl parathion and fenpropathrin. , 2010, Journal of environmental management.

[50]  G. Pantazis,et al.  Expression of EAAT-1 distinguishes choroid plexus tumors from normal and reactive choroid plexus epithelium , 2009, Acta Neuropathologica.

[51]  J. Taylor,et al.  Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. , 2008, Biochimica et biophysica acta.

[52]  R McKinlay,et al.  Endocrine disrupting pesticides: implications for risk assessment. , 2008, Environment international.

[53]  L. A. McInnes,et al.  EAAT2 regulation and splicing: relevance to psychiatric and neurological disorders , 2007, Molecular Psychiatry.

[54]  Wei Gu,et al.  p53 ubiquitination: Mdm2 and beyond. , 2006, Molecular cell.

[55]  Z. Weng,et al.  A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome , 2006, Cell.

[56]  R. Bridges,et al.  The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. , 2005, Pharmacology & therapeutics.

[57]  J. Nutt,et al.  Parkinson's disease , 2004, The Lancet.

[58]  R. Swanson,et al.  Astrocyte glutamate transport: Review of properties, regulation, and physiological functions , 2000, Glia.

[59]  K. P. Lehre,et al.  Brain Glutamate Transporter Proteins Form Homomultimers* , 1996, The Journal of Biological Chemistry.